p450 - publications

Predict more p450 - ligand interactions now!

1. Curr Drug Metab. 2012 Apr 10. [Epub ahead of print]

The influence of CYP2C19 genetic polymorphism on the
pharmacokinetics/pharmacodynamics of proton pump inhibitor-containing
Helicobacter pylori treatments.

Serrano DR, Torrado S, Torrado-Santiago S, Gisbert JP.

Facultad de Farmacia, Universidad Complutense. Plaza Ramón y Cajal SN 28040
Madrid. Spain. torrado2@farm.ucm.es.

Proton pump inhibitors (PPIs) are the most potent acid suppressants available.
PPIs undergo hepatic metabolism via the CYP2C system for the isoforms CYP2C19 and
CYP3A4 in particular. Genetic polymorphisms in CYP2C19 may affect the metabolism
of individual PPIs to different extents. Although PPIs are highly effective as a
class, differences in their pharmacokinetics, such as bioavailability and
metabolism, may translate into differences in clinical outcomes. In Helicobacter
pylori infection, a significantly lower eradication rate was seen in extensive
metabolisers with omeprazole but no with rabeprazole.

PMID: 22493986 [PubMed - as supplied by publisher]